Trust Signals
Key Takeaways
- Open growth plates are a hard biological requirement, confirmed by bone-age X-ray, not chronological age, before any height intervention makes sense.
- Mecasermin (recombinant IGF-1) is the strongest non-HGH option with FDA approval, showing roughly 5 to 6 cm per year height velocity increase in year one for children with severe primary IGF-1 deficiency.
- GnRH agonists preserve height potential in precocious puberty by delaying bone-age advancement, with reported adult height gains of 3 to 10 cm depending on initiation age.
- GHRH analogs and GHRPs (CJC-1295, ipamorelin, sermorelin) raise endogenous GH but have no large RCT evidence specifically for centimeter-level height gain in humans.
- No peptide or hormone grows bone after growth plate fusion. Any claim to the contrary is unsupported by human clinical evidence.
Direct Answer: What Are the Best Peptides and Hormones for Height Besides HGH?
The best evidence-supported options are mecasermin (recombinant IGF-1) for children with severe IGF-1 deficiency, GnRH agonists for precocious puberty, and sermorelin for GH-deficient children. CJC-1295, ipamorelin, and MK-677 raise GH and IGF-1 but lack height-specific RCT data. All require open growth plates to work at all.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: All Major Compounds Graded
- How Growth Plate Biology Limits Every Compound
- IGF-1 (Mecasermin): The Strongest Non-HGH Option
- GnRH Agonists and Aromatase Inhibitors: The Bone-Age Strategy
- GHRH Analogs and GHRPs: Sermorelin, CJC-1295, Ipamorelin
- MK-677 (Ibutamoren): The Oral Ghrelin Mimetic
- What Most Pages Get Wrong About Peptides and Height
- Honest Head-to-Head: Peptides vs. Approved Drugs vs. HGH
- Label and COA Literacy: How to Evaluate a Product
- FAQ
- Sources
Evidence Ledger: All Major Compounds Graded
| Compound | Best Evidence Type | Effect on Height | Confidence | Key Caveat |
|---|---|---|---|---|
| Mecasermin (rIGF-1) | Human RCT, FDA-approved trial program | Positive, moderate-large in IGF-1 deficiency | High | Only approved for severe primary IGF-1 deficiency |
| GnRH agonists (leuprolide) | Human RCT in precocious puberty | Positive, preserves height potential | High (for precocious puberty), Moderate (idiopathic short stature) | Effect depends heavily on age of initiation |
| Aromatase inhibitors (anastrozole, letrozole) | Small human RCT, off-label | Positive trend in predicted adult height in boys | Moderate | Long-term bone density and reproductive safety unclear |
| Sermorelin (GHRH analog) | Small human trials, FDA-approved historically | Positive in GH-deficient children | Moderate | Withdrawn from market; no current approved formulation for pediatric use |
| CJC-1295 (GHRH analog with DAC) | Small human PK study (GH/IGF-1 levels); no height RCT | Raises GH/IGF-1; height outcome not studied in humans | Very Low (for height) | Research compound only; no pediatric safety data |
| Ipamorelin (GHRP) | Animal data, small human GH-release studies | Raises GH pulse; height outcome not studied in humans | Very Low (for height) | Research compound only; no approved use |
| MK-677 (ibutamoren, oral ghrelin mimetic) | Small human study in GH-deficient children; adult trials | Increases height velocity in one small pediatric study | Low | Not FDA-approved; insulin resistance signal in adults |
| GHRP-2 / GHRP-6 | Animal and small adult human PK data | GH pulse stimulation; no height outcome data | Very Low (for height) | Research compound; cortisol and prolactin elevation noted |
How Growth Plate Biology Limits Every Compound
Longitudinal bone growth happens exclusively at the epiphyseal growth plate, a cartilage layer at each end of long bones. Chondrocytes in the proliferative zone divide in response to IGF-1, which is stimulated downstream of GH binding to liver GH receptors. GH binds the GHR receptor (a cytokine-family receptor), activating JAK2-STAT5b signaling to transcribe IGF-1 mRNA. Circulating IGF-1 then acts on IGF-1R receptors in growth plate chondrocytes to drive proliferation and hypertrophy.
The closing event is estrogen-driven. Estrogen, produced from androgens by aromatase in both sexes, accelerates chondrocyte senescence and triggers ossification of the growth plate. Once fused, no hormone or peptide can reopen cartilage or re-establish a proliferative zone. This is why bone age assessment (left-hand X-ray scored by the Greulich-Pyle atlas) is clinically mandatory before any height intervention. A child who is Risser stage 4 or 5 has no biologically available growth plate to stimulate.
IGF-1 (Mecasermin): The Strongest Non-HGH Option
Mecasermin (brand name Increlex) is recombinant human IGF-1 approved by the FDA for growth failure in children with severe primary IGF-1 deficiency, defined as height standard deviation score below negative 3, low IGF-1, and normal or elevated GH. It bypasses the GH step entirely and acts directly on IGF-1R in chondrocytes.
In the pivotal clinical trials supporting FDA approval (Ranke et al. and the Increlex prescribing information dataset), children treated with mecasermin showed mean height velocity increases of approximately 5 to 6 cm per year in year one compared to pretreatment baseline, with attenuating gains in subsequent years. The prescribed dose range is 0.04 to 0.12 mg per kg administered subcutaneously twice daily with meals to reduce hypoglycemia risk, which is the most significant adverse effect due to IGF-1's insulin-like activity.
Mecasermin-IGFBP3 (Iplex) was a related product combining IGF-1 with its binding protein; it was withdrawn from the pediatric growth indication following a legal settlement and is no longer available for this use.
GnRH Agonists and Aromatase Inhibitors: The Bone-Age Strategy
Rather than adding a growth signal, these drugs slow the clock that closes growth plates. Estrogen is the primary driver of epiphyseal fusion. Two drug classes exploit this:
GnRH agonists (leuprolide, triptorelin, histrelin): Paradoxically, continuous GnRH receptor stimulation desensitizes the pituitary, shutting down LH and FSH secretion and thus gonadal sex steroid production. In central precocious puberty, this extends the window of open growth plates. A 2011 Cochrane review found that GnRH agonist treatment in precocious puberty improved final adult height, with most included studies showing gains of 3 to 10 cm over predicted height at initiation, though heterogeneity across studies is significant.
Aromatase inhibitors (anastrozole, letrozole): These block the enzyme that converts testosterone to estradiol. In boys, small RCTs (Wickman et al., Dunkel et al.) showed that anastrozole treatment slowed bone-age advancement and improved predicted adult height by a few centimeters compared to placebo. Effects in girls are less clear and safety data are limited. Neither drug is approved for height augmentation; both are off-label uses in pediatric endocrinology.
GHRH Analogs and GHRPs: Sermorelin, CJC-1295, Ipamorelin
Sermorelin is a 29-amino acid fragment of endogenous GHRH (growth hormone-releasing hormone) that binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and pulsatile release. It was FDA-approved under the brand Geref for growth failure diagnosis and treatment in children; it was withdrawn for commercial rather than safety reasons. Its key mechanistic advantage over exogenous HGH is that it preserves the pituitary's feedback sensitivity, meaning GH is released in natural pulses rather than sustained supraphysiologic levels. Evidence in GH-deficient children showed height velocity improvements, but it was less studied than HGH and no longer has an approved pediatric product in the US.
CJC-1295 is a synthetic GHRH analog modified with Drug Affinity Complex (DAC) technology, which binds albumin and extends its half-life from minutes to days. A small published Phase II study by Teichman et al. in healthy adults showed that a single dose produced sustained GH and IGF-1 elevation for up to 6 days. This study did not measure height. No human pediatric height data exist for CJC-1295. It is a research compound with no approved indication.
Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist and GHRP. Unlike GHRP-2 and GHRP-6, it does not substantially raise cortisol or prolactin at standard doses, which is its primary mechanistic advantage within its class. It produces GH pulses in rodent and human studies, but no published human RCT has measured height as an outcome. It is a research compound only.
The combination of a GHRH analog plus a GHRP produces synergistic GH release because the two pathways converge on somatotrophs independently. This is the mechanistic rationale for "stacking" but it still does not constitute evidence of height gain in humans.
MK-677 (Ibutamoren): The Oral Ghrelin Mimetic
MK-677 is an orally active, non-peptide ghrelin mimetic that activates GHSR-1a. Its oral bioavailability sets it apart from injectable peptides. Early-phase clinical studies conducted as part of Merck's development program examined MK-677 in children with GH deficiency and reported increased height velocity. However, those studies were small and short-term, and the full dataset has not been published in a peer-reviewed journal with sufficient detail to assess methodology independently. No large RCT of MK-677 for height has been published.
The pharmacokinetic issue with MK-677 is that it raises GH and IGF-1 levels in a sustained, non-pulsatile pattern rather than the physiologic burst pattern. Adult studies lasting up to 2 years have shown that this leads to measurable increases in fasting insulin and insulin resistance (Murphy et al., 1998). In pediatric populations, the long-term metabolic consequences are unknown. MK-677 has no FDA approval for any indication.
What Most Pages Get Wrong About Peptides and Height
This is the section competitors skip.
1. Conflating GH release with height gain. Every GHRP and GHRH analog page will cite a study showing "elevated IGF-1" or "GH pulse amplitude increased." That is a surrogate marker. The question is whether open growth plates, in a child with suboptimal GH secretion, translate that elevated IGF-1 into additional chondrocyte proliferation and net centimeter gains. This downstream step has not been proven for CJC-1295, ipamorelin, GHRP-2, or GHRP-6 in any controlled human height study.
2. Ignoring the adult/adolescent distinction. Most readers searching this question are adults or parents of adolescents. Almost every GHRH/GHRP study reporting GH elevation was conducted in adults. Adult growth plates are fused. The GH elevation data from those studies is biologically irrelevant to height.
3. The purity and sequence problem. Research-grade peptides purchased outside a pharmaceutical supply chain frequently contain truncated sequences, incorrect disulfide bonding, or bacterial endotoxin contamination. A peptide with one incorrect amino acid may have zero receptor activity. No commodity article mentions this. A COA showing "98 percent pure" by UV absorbance at 214 nm does not confirm correct sequence; only mass spectrometry confirms molecular identity.
4. Stability is not discussed. GHRH analogs are susceptible to oxidation and peptide bond hydrolysis in solution. CJC-1295 without DAC (sermorelin-equivalent) degrades within hours at room temperature and meaningfully over days even refrigerated. Lyophilized powder is stable for months to years at minus 20 degrees Celsius, but reconstituted solutions should be used within 2 to 4 weeks refrigerated and protected from light. Repeated freeze-thaw cycles fragment the peptide. None of this is on most product pages.
5. Regulatory and legal reality. Using unapproved research compounds in children is not equivalent to a physician prescribing an FDA-approved drug. It creates liability for any provider who administers them and exposes children to unquantified risk. The FDA's 503B compounding rules do not automatically legitimize a peptide for pediatric use.
Honest Head-to-Head: Peptides vs. Approved Drugs vs. HGH
| Compound | FDA Approval for Height | Route | Height Evidence Quality | Key Advantage | Key Disadvantage | Verdict vs. HGH |
|---|---|---|---|---|---|---|
| Recombinant HGH (somatropin) | Yes (multiple indications) | SC injection daily | High | Most studied, largest effect size | Cost, injection burden, potential IGF-1 excess | Reference standard |
| Mecasermin (IGF-1) | Yes (severe primary IGF-1 deficiency) | SC injection twice daily | High | Works when GHR is defective; bypasses GH axis | Hypoglycemia risk; twice-daily dosing | Wins in GH receptor insensitivity syndromes |
| GnRH agonists | Yes (precocious puberty) | Injection or implant | High (precocious puberty), Moderate (other) | Preserves growth window; proven height gain | Not useful without accelerated bone age | Complementary, not a replacement |
| Aromatase inhibitors | No (off-label) | Oral | Moderate | Oral; may add effect in boys when combined with HGH | Long-term bone/reproductive safety unknown | Adjunct only; loses on safety certainty |
| Sermorelin | Formerly yes; currently no approved product | SC injection | Moderate | Physiologic pulsatile GH; lower cost historically | No current approved pediatric formulation | Loses on availability |
| CJC-1295 | No | SC injection | Very Low for height | Long half-life; convenient dosing | No human height data; purity risk | Loses clearly on evidence |
| Ipamorelin | No | SC injection | Very Low for height | Selective; low cortisol elevation vs. other GHRPs | No human height data; research compound | Loses clearly on evidence |
| MK-677 | No | Oral | Low | Oral convenience; sustained IGF-1 elevation | Non-pulsatile GH; insulin resistance; no approval | Loses on safety profile and evidence |
Label and COA Literacy: How to Evaluate a Product
If you or a physician are evaluating a compounded or research-grade peptide for GH stimulation, here is what to require and how to interpret it:
- Purity by HPLC: Greater than 98 percent is the minimum floor. Understand that HPLC purity measures the peptide peak relative to all detected peaks at the chosen wavelength. It does not tell you whether the main peak is the correct peptide.
- Molecular weight by mass spectrometry: This is the confirmation you actually need. If the COA lacks an MS readout showing the expected molecular ion, you cannot confirm identity. CJC-1295 without DAC has a molecular weight of approximately 3367 Da; CJC-1295 with DAC is approximately 3648 Da. These are not interchangeable.
- Endotoxin testing (LAL assay): For injectable peptides, endotoxin below 1 EU per mg is the standard reference point. Bacterial endotoxin causes fever, sepsis-like reactions, and systemic inflammation. Many research peptide suppliers do not test for endotoxin.
- Sterility: Sterility testing per USP standards should be confirmed for any product intended for injection. Lyophilized powder is not automatically sterile.
- Reconstitution: Use bacteriostatic water (0.9 percent benzyl alcohol) for multi-use vials, not sterile water. Bacteriostatic water retards microbial growth after the septum is punctured. Sterile water vials should be used in one draw and discarded.
- Reconstitution math example: A 5 mg vial of CJC-1295 reconstituted with 2.5 mL bacteriostatic water yields 2 mg per mL or 2000 mcg per mL. A 100 mcg dose is then 0.05 mL drawn on a U-100 insulin syringe, which is 5 units on the syringe scale.
- Signs of degradation: Discoloration beyond faint yellow, visible particulate matter, or an odor indicate degradation or contamination. Discard immediately.
FAQ
What are the best peptides and hormones for height besides HGH?
The most evidence-supported options in children with open growth plates are mecasermin (recombinant IGF-1), GnRH agonists to delay puberty, and aromatase inhibitors to slow bone age. GHRH analogs like CJC-1295 and GHRPs like ipamorelin stimulate endogenous GH release, but evidence for height gain specifically is limited to animal and small clinical data.
Can CJC-1295 or ipamorelin increase height?
Possibly in children with open growth plates and suboptimal endogenous GH secretion, but there are no published RCTs showing height gain specifically from these peptides in humans. They raise GH and IGF-1 levels transiently, which is the biological precondition for growth, but that does not prove centimeter outcomes.
Does IGF-1 (mecasermin) increase height in children?
Yes. Mecasermin is FDA-approved for growth failure in children with severe primary IGF-1 deficiency. Clinical trials show height velocity increases of roughly 5 to 6 cm per year in the first year of treatment versus baseline, with continued but attenuating gains in subsequent years.
What role do GnRH agonists play in increasing adult height?
GnRH agonists like leuprolide suppress sex hormone production, slowing the bone-age advancement that closes growth plates. In children with central precocious puberty, this can preserve height potential. Average adult height gain reported in studies ranges from roughly 3 to 10 cm depending on age of initiation and duration of treatment.
Can peptides increase height after growth plates close?
No. Once epiphyseal plates fuse, longitudinal bone growth is biologically impossible regardless of hormone or peptide used. No compound, dose, or protocol overcomes fused growth plates. Claims suggesting otherwise are unsupported by any human clinical evidence.
Are aromatase inhibitors used to increase height?
Yes, off-label. Aromatase inhibitors like anastrozole and letrozole slow conversion of androgens to estrogen, which is the primary driver of growth plate fusion. Small RCTs in boys with short stature show modest improvements in predicted adult height, but long-term safety data including bone density effects are still being studied.
Is sermorelin a real alternative to HGH for height?
Sermorelin is a GHRH analog that stimulates pituitary GH release. It was FDA-approved for growth failure in children and withdrawn for commercial rather than safety reasons. Its mechanism is more physiologic than exogenous HGH because it preserves pulsatile release. Evidence for height gain is moderate in GH-deficient children but thin in idiopathic short stature.
What is the difference between a GHRP and a GHRH analog for height?
GHRH analogs (sermorelin, CJC-1295, tesamorelin) act on GHRH receptors at the pituitary to stimulate GH synthesis and release. GHRPs and ghrelin mimetics (ipamorelin, GHRP-2, GHRP-6, MK-677) act on ghrelin receptors (GHSR-1a) to stimulate GH release via a different pathway. Combining both classes produces a synergistic GH pulse.
Does MK-677 (ibutamoren) increase height in children?
MK-677 is an oral ghrelin mimetic that raises sustained GH and IGF-1 levels. Early-phase clinical work from Merck's development program reported increased height velocity in GH-deficient children, but those studies were small and short-term. MK-677 is not FDA-approved for any use, lacks large RCT data for height, and raises concerns about sustained non-pulsatile IGF-1 elevation and insulin resistance.
What is the minimum age or growth plate status required for height peptides to work?
Open growth plates are an absolute biological requirement. Bone age, not chronological age, determines this. A pediatric endocrinologist can assess bone age via a left-hand X-ray (Greulich-Pyle method). Treatment is only rational while Risser stage 0 to 2 is present, roughly before age 14 to 16 in most individuals, though this varies.
Are peptides for height legal and safe to use?
Mecasermin and GnRH agonists are FDA-approved drugs with defined safety profiles. GHRH analogs and GHRPs like CJC-1295 and ipamorelin are research compounds in the US, not approved for clinical use outside trials. MK-677 has no FDA approval. Using unapproved peptides in children carries unknown safety risks and legal exposure for providers.
How do I read a COA for a peptide intended to raise GH?
Look for purity above 98 percent by HPLC, correct molecular weight confirmed by mass spectrometry, absence of endotoxins (LAL test result below 1 EU/mg for injectable use), and sterility confirmation. Reject any COA older than 12 months or lacking MS confirmation, as incorrect sequence or truncated peptides are common adulterants.
Sources
- Ranke MB, et al. Treatment of children with growth hormone deficiency and idiopathic short stature. Horm Res Paediatr. (Multiple publications from the KIGS registry).
- Increlex (mecasermin) US Prescribing Information. Ipsen Biopharmaceuticals. FDA-approved label.
- Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366-2377.
- Mul D, et al. A Dutch growth hormone working group consensus statement on the diagnosis and treatment of central precocious puberty. Eur J Endocrinol. 2015.
- Wickman S, et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet. 2001;357(9270):1743-1748.
- Dunkel L, Quinton R. Transition in endocrinology: induction of puberty. Eur J Endocrinol. 2014;170(6):R229-R239.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Murphy MG, et al. MK-0677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325.
- Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford University Press; 1959.
- FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.
- USP General Chapter 85: Bacterial Endotoxins Test. United States Pharmacopeia.
- Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001;54(5):311-316.